NYSE:GMED • US3795772082
The current stock price of GMED is 87.22 USD. In the past month the price decreased by -5.67%. In the past year, price increased by 3.92%.
ChartMill assigns a technical rating of 3 / 10 to GMED. When comparing the yearly performance of all stocks, GMED turns out to be only a medium performer in the overall market: it outperformed 51.83% of all stocks.
ChartMill assigns a fundamental rating of 6 / 10 to GMED. GMED gets an excellent profitability rating and is at the same time showing great financial health properties.
Over the last trailing twelve months GMED reported a non-GAAP Earnings per Share(EPS) of 3.56. The EPS increased by 22.76% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 15.3% | ||
| ROA | 8.32% | ||
| ROE | 9.63% | ||
| Debt/Equity | 0 |
21 analysts have analysed GMED and the average price target is 107.03 USD. This implies a price increase of 22.71% is expected in the next year compared to the current price of 87.22.
For the next year, analysts expect an EPS growth of 25.18% and a revenue growth 16.37% for GMED
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 19.41 | 197.518B | ||
| ISRG | INTUITIVE SURGICAL INC | 46.82 | 175.875B | ||
| SYK | STRYKER CORP | 24.2 | 139.086B | ||
| BSX | BOSTON SCIENTIFIC CORP | 21.16 | 108.957B | ||
| IDXX | IDEXX LABORATORIES INC | 41.66 | 51.801B | ||
| BDX | BECTON DICKINSON AND CO | 11.28 | 51.46B | ||
| EW | EDWARDS LIFESCIENCES CORP | 25.71 | 46.035B | ||
| RMD | RESMED INC | 20.01 | 37.897B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 15.66 | 36.095B | ||
| DXCM | DEXCOM INC | 25.78 | 26.58B |
View all stocks in the Health Care Equipment Industry | View all stocks in the Health Care Sector | View all stocks on the New York Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find more growth stocks the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
Globus Medical, Inc. operates as a medical device company that develops and commercializes healthcare solutions. The company is headquartered in Audubon, Pennsylvania and currently employs 5,300 full-time employees. The company went IPO on 2012-03-08. The firm offers a portfolio of differentiated technologies that are used to treat a variety of musculoskeletal conditions. Musculoskeletal Solutions consist primarily of implantable devices, biologics, accessories, and surgical instruments used in a range of spinal, orthopedic and neurosurgical procedures. Its spine products address the conditions affecting the spine, including degenerative conditions, deformities, tumors, and trauma. The company provides solutions that facilitate both open and minimally invasive surgery techniques. The company includes traditional fusion implants, such as pedicle screws and rod systems, and others. Its orthopedic trauma solutions are designed to treat a variety of orthopedic fracture patterns and patient anatomies in the upper and lower extremities, as well as the hip.
GLOBUS MEDICAL INC - A
2560 General Armistead Ave
Audubon PENNSYLVANIA 19403 US
CEO: David M. Demski
Employees: 5300
Phone: 16109301800
Globus Medical, Inc. operates as a medical device company that develops and commercializes healthcare solutions. The company is headquartered in Audubon, Pennsylvania and currently employs 5,300 full-time employees. The company went IPO on 2012-03-08. The firm offers a portfolio of differentiated technologies that are used to treat a variety of musculoskeletal conditions. Musculoskeletal Solutions consist primarily of implantable devices, biologics, accessories, and surgical instruments used in a range of spinal, orthopedic and neurosurgical procedures. Its spine products address the conditions affecting the spine, including degenerative conditions, deformities, tumors, and trauma. The company provides solutions that facilitate both open and minimally invasive surgery techniques. The company includes traditional fusion implants, such as pedicle screws and rod systems, and others. Its orthopedic trauma solutions are designed to treat a variety of orthopedic fracture patterns and patient anatomies in the upper and lower extremities, as well as the hip.
The current stock price of GMED is 87.22 USD. The price decreased by -1.18% in the last trading session.
GMED does not pay a dividend.
GMED has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
21 analysts have analysed GMED and the average price target is 107.03 USD. This implies a price increase of 22.71% is expected in the next year compared to the current price of 87.22.
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on GMED.
GLOBUS MEDICAL INC - A (GMED) currently has 5300 employees.